drugset
drugset / Trial / NCT01350440

Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia

NCT01350440 ↗

Phase 2 Completed 5 enrolled University of South Florida Baxter Healthcare Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a preliminary study to determine the safety and efficacy of intravenous immune globulin in treating Spinocerebellar Ataxia. The investigators aim to assess changes in clinical measures of disease severity before and after treatment.

Timeline

Start
2011-08
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Intravenous Immune Globulin Protein / enzyme biologic — Intravenous

Indications

cerebellar ataxia